Accelerated streptokinase and enoxaparin in ST-segment elevation acute myocardial infarction (the ASENOX study)

Kardiologia Polska

Volumn 60, Issue 5, 2004, Pages 441-446

  Tatu Chitoiu, Gabriel ^a,d   Teodorescu, Cristina ^a   Capraru, Petre ^a   Guran, Manuela ^a   Istratescu, Oana ^a   Tatu Chitoiu, Monica Dan Alexandrina ^a   Bumbu, Aurelia ^b   Chioncel, Valentin ^c   Dorobantu, Maria ^a  

^a Emergency Hospital Ilfov   (Romania)

^b VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^c Sfantul Ioan Hospital   (Romania)

^d Spitalul Clinic de Urgenta Floreasca   (Romania)

Author keywords

Acute myocardial infarction; Enoxaparin; Streptokinase; Thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; CREATINE KINASE; CREATINE KINASE MB; ENOXAPARIN; HEPARIN; STREPTOKINASE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY REPERFUSION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; HUMAN; HYPOTENSION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MORTALITY; ST SEGMENT ELEVATION; STROKE;

EID: 2642526373     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. The GUSTO investigators. An international randomised trial comparing four thrombolytic strategies for acute myocardial infarction. N. Engl. J. Med. 1993, 329, 673-682.
2. Bode C., Smalling R.W., Berg G. et al.: Randomised comparison of coronary thrombolysis achieved with double bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators. Circulation 1996, 94, 891-898.
3. International Joint Efficacy Comparison of Thrombolytics. Randomised double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet 1995, 346, 329-336.
4. Global Use of Strategies to Open Occluded Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N. Engl. J. Med. 1997, 337, 1118-1123.
5. InTIME-II Investigators. Intravenous NPA for the treatment of infarcting myocardium early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur. Heart J. 2000, 21 (24), 2005-2013.
6. ASSENT-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001, 358, 605-13.
7. Ross A.M., Molhoek P., Lundergan C. et al.: Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 2001, 104, 648-652.
8. Simoons M., Krzeminska-Pakula M., Alonso A. et al.: Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study. Eur. Heart J. 2002, 23, 1282-1290.
9. Antma̧n E.M., Louwerenburg H.W., Baars H.F. et al.: Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 2002, 105, 1642-1649.
10. Baird S.H., Menown I.B., Mcbride S.J. et al.: Randomised comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction. Eur. Heart J. 2002, 23, 627-632.
11. White H.: Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001, 358, 1855-1863.
12. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992, 339, 753-770.
13. Vorcheimer D.A., Baruch L., Thompson T.D. et al.: North American vs Non-North American streptokinase use in GUSTO-I: impact of protocol deviation on mortality benefit of tPA. Circulation 1997, 96, 1-535.
14. Turpie A.G.G., Antman E.M.: Low molecular weight heparins in the treatment of acute coronary syndromes. Arch. Intern. Med. 2001, 161, 1484-90.
15. Ryan T.J., Antman E.M., Brooks N.H. et. al.: 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J. Am. Coll. Cardiol. 1999, 34, 890-911.
16. Six A.J., Louwerenburg H.W., Braams R. et al.: A double-blind randomized multicenter dose-ranging trial of intravenous streptokinase in acute myocardial infarction. Am. J. Cardiol. 1990, 65, 119-123.
17. Deutsche E.: Endogenous and exogenous thrombolysis. Thrombosis et Diathesis Haemorrhagica 1971, (Suppl 47), 145.
18. Anschelevich M., Anschelevich I., Kochkaryov F.: Safety of a new accelerated streptokinase regimen in acute myocardial infarction. Eur. Heart J. 1996, 17 (Abstract suppl), 203.
19. Esteves F.P., Esteves P.J., Passos L.C. et al.: Coronary patency 90 minutes after intravenous (750,000 U, in 15 min) streptokinase in acute myocardial infarction - TROMBA study. Eur. Heart J. 1996, 17 (Abstract suppl), 203.